Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2013
Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma GroupA Gronchi, C Colombo, C Le Péchoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationJ Rodon, H Prenen, A Sacher, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 11, 2014
Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma groupA T Falk, L Moureau-Zabotto, M Ouali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trialN Penel, A Italiano, J Wallet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyN Penel, G D Demetri, J Y Blay, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2025
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trialJ-Y Blay, Q Devin, M Toulmonde, et al.
Pageof 11